phenindione has been researched along with Stroke in 5 studies
Phenindione: An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of our study was to compare the time spent within the target INR or Time in Therapeutic Range (TTR) of patients treated with fluindione to that of patients treated with warfarin for non-valvular atrial fibrillation (NVAF) and followed in general practice, with the hypothesis of a better TTR with warfarin, which is the VKA most commonly prescribed in France." | 8.12 | [Comparative study in primary care of the stability of INR in patients treated with warfarin or fluindione for atrial fibrillation. The FLOWER study (FLuindione Or WarfarinE - Result INR)]. ( Berland, M; Charuel, E; Giron, A; Lambert, C; Ménini, T; Pereira, B; Poinas, L; Schmidt, J; Vorilhon, P, 2022) |
| "Etiology identification of the stroke included cardiogenic pathology and coagulopathy, but acitretin treatment was considered the likeliest explanation." | 7.71 | Acitretin-associated thrombotic stroke. ( Davani, S; Kantelip, JP; Muret, P; Royer, B; Ziegler, F, 2002) |
| "The aim of our study was to compare the time spent within the target INR or Time in Therapeutic Range (TTR) of patients treated with fluindione to that of patients treated with warfarin for non-valvular atrial fibrillation (NVAF) and followed in general practice, with the hypothesis of a better TTR with warfarin, which is the VKA most commonly prescribed in France." | 4.12 | [Comparative study in primary care of the stability of INR in patients treated with warfarin or fluindione for atrial fibrillation. The FLOWER study (FLuindione Or WarfarinE - Result INR)]. ( Berland, M; Charuel, E; Giron, A; Lambert, C; Ménini, T; Pereira, B; Poinas, L; Schmidt, J; Vorilhon, P, 2022) |
| " We extracted data for adults (aged ≥18 years) with non-valvular atrial fibrillation who received their first prescription for a vitamin K antagonist (fluindione, warfarin, or acenocoumarol) between Jan 1, 2011, and Nov 30, 2012, and who were either switched to a NOAC (dabigatran or rivaroxaban) or maintained on the vitamin K antagonist." | 3.81 | Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. ( Bertrand, M; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M, 2015) |
| "Etiology identification of the stroke included cardiogenic pathology and coagulopathy, but acitretin treatment was considered the likeliest explanation." | 3.71 | Acitretin-associated thrombotic stroke. ( Davani, S; Kantelip, JP; Muret, P; Royer, B; Ziegler, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giron, A | 1 |
| Lambert, C | 1 |
| Berland, M | 1 |
| Schmidt, J | 1 |
| Poinas, L | 1 |
| Charuel, E | 1 |
| Ménini, T | 1 |
| Pereira, B | 1 |
| Vorilhon, P | 1 |
| Annweiler, C | 1 |
| Ferland, G | 1 |
| Barberger-Gateau, P | 1 |
| Brangier, A | 1 |
| Rolland, Y | 1 |
| Beauchet, O | 1 |
| Bouillon, K | 1 |
| Bertrand, M | 1 |
| Maura, G | 1 |
| Blotière, PO | 1 |
| Ricordeau, P | 1 |
| Zureik, M | 1 |
| Royer, B | 1 |
| Ziegler, F | 1 |
| Muret, P | 1 |
| Davani, S | 1 |
| Kantelip, JP | 1 |
| Ansell, J | 1 |
| Hollowell, J | 1 |
| Pengo, V | 1 |
| Martinez-Brotons, F | 1 |
| Caro, J | 1 |
| Drouet, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| English: Current Perspective of the Status of Anticoagulation in Clinical Practice in Primare Care. Spanish: Perspectiva Actual de la sitUación de la anticoaguLación en la práctica clínica de Atención Primaria.[NCT02273609] | 1,524 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for phenindione and Stroke
| Article | Year |
|---|---|
[Comparative study in primary care of the stability of INR in patients treated with warfarin or fluindione for atrial fibrillation. The FLOWER study (FLuindione Or WarfarinE - Result INR)].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Flowers; Hemorrhage; Humans; Internati | 2022 |
Vitamin K antagonists and cognitive impairment: results from a cross-sectional pilot study among geriatric patients.
Topics: Aged; Aged, 80 and over; Aging; Anticoagulants; Atrial Fibrillation; Cognition Disorders; Cross-Sect | 2015 |
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hem | 2015 |
Acitretin-associated thrombotic stroke.
Topics: Acitretin; Analgesics; Anticoagulants; Antiemetics; Dextropropoxyphene; Domperidone; Female; Headach | 2002 |
Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; C | 2007 |